The paper describes the treatment of a 27-year-old woman with a history of infertility, heavy menstrual periods, and severe endometriosis with bilateral hydrosalpinx. The patient received hormonal treatment with triptorelin …
Innovent & HUTCHMED Win China Approval for Breakthrough Endometrial Cancer Therapy | IVBIY Stock News StockTitan
Innovent & HUTCHMED Win China Approval for Breakthrough Endometrial Cancer Therapy | HCM Stock News StockTitan
Waldenström macroglobulinemia (WM) is a relatively rare hematological malignancy characterized by serum monoclonal IgM gammopathy and bone marrow infiltration of lymphoma cells (small B lymphocytes, plasmacytoid lymphocytes, or plasma cells). …
This review investigates the therapeutic potential of butyrate, a short-chain fatty acid (SCFA) produced by gut microbiota, in the prevention and treatment of various gynecological diseases, including polycystic ovary syndrome …
NMPA Grants Conditional Approval to Fruquintinib Plus Sintilimab for pMMR Endometrial Cancer OncLive
Hutchmed endometrial cancer treatment gets conditional approval in China ShareCast
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer GlobeNewswire
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer Yahoo Canada Finance
HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer Yahoo Finance